BCA
CHRS icon

Berman Capital Advisors’s Coherus Oncology CHRS Stock Holding History

Berman Capital Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$6K Buy
430
+163
+61% +$2.39K ﹤0.01% 1367
2021
Q2 		$3K Buy
+267
New +$3.78K ﹤0.01% 1468

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Berman Capital Advisors's CHRS Position: Q3 2021 in Review

Berman Capital Advisors increased its Coherus Oncology (CHRS) stake by 61% in Q3 2021, buying an estimated $2.39K and bringing the position to 430 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #1367.

Berman Capital Advisors first reported a position in CHRS in Q2 2021 and has held it in 2 quarters since. 187 funds tracked by Wall St. Rank hold CHRS as of Q3 2021.

  • Berman Capital Advisors held 430 shares of Coherus Oncology worth $6K as of Q3 2021.
  • Berman Capital Advisors bought 163 Coherus Oncology shares in Q3 2021, an estimated $2.39K.
  • Coherus Oncology made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1367 holding.
  • Berman Capital Advisors first reported a position in Coherus Oncology in Q2 2021 and has held it in 2 quarters since.
  • 187 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.